Tyr Pharma's stock surged on positive data for pulmonary sarcoidosis treatment, but cash balance risk keeps investors ...

Fintel reports that on January 6, 2025, Cantor Fitzgerald initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a Overweight ...

Cantor Fitzgerald initiated coverage of aTyr Pharma (ATYR) with an Overweight rating. aTyr Pharma’s lead drug Efzofitimod is in two trials for ...

Equities research analysts at Cantor Fitzgerald started coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research report issued to clients and investors on Monday,Briefing.com ...

In this article, we are going to take a look at where aTyr Pharma, Inc. (NASDAQ:ATYR) stands against other best multibagger stocks. November has been an eventful month so far for the market as the ...

Following the event, a replay of the presentation will be available on the aTyr website for at least 30 days. For more information, contact [email protected]. aTyr is a clinical ...

aTyr Pharma, Inc. announced the appointment of Eric Benevich to its Board of Directors, effective December 10, 2024. Benevich, currently the Chief Commercial Officer at Neurocrine Biosciences ...

Detailed price information for Atyr Pharma Inc (ATYR-Q) from The Globe and Mail including charting and trades.

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on aTyr Pharma (ATYR – Research Report) and keeping the price target at $35.00. Pick the best stocks and maximize your ...

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1.